Allergan may be headed for a rebound. The last time AGN reported, the company announced that a key product in its pipeline for macular degeneration needed additional work, and approval was going to be delayed.
http://seekingalpha.com/article/1597872-cramers-mad-money-will-allergans-stock-get-a-facelift-8-1-13?source=feed
http://seekingalpha.com/article/1597872-cramers-mad-money-will-allergans-stock-get-a-facelift-8-1-13?source=feed
No comments:
Post a Comment